Discover open access scientific publications

Search, annotate, share and cite publications

Publications by P.D. Cole

Response-Adapted Treatment With Nivolumab and Brentuximab Vedotin in Young Patients With Relapsed/Refractory Classical Hodgkin Lymphoma: Checkmate 744 Subgroup Analyses

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Related publications

Nivolumab for Relapsed/Refractory Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure – Polish Lymphoma Research Group Real-Life Experience

Acta Haematologica Polonica
OncologyHematology
2018English

Pulmonary Toxicity in Paediatric Patients With Relapsed or Refractory Hodgkin Lymphoma Receiving Brentuximab Vedotin

British Journal of Haematology
Hematology
2018English

Combination of Nivolumab and Bendamustine in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Chemoimmunotherapy With Brentuximab Vedotin Combined With Ifosfamide, Gemcitabine, and Vinorelbine Is Highly Active in Relapsed or Refractory Classical Hodgkin Lymphoma

Bone Marrow Transplantation
TransplantationHematology
2019English

Brentuximab Vedotin for Relapsed or Refractory Hodgkin Lymphoma: Experience in Turkey

Annals of Hematology
MedicineHematology
2014English

Profile of Brentuximab Vedotin and Its Potential in the Treatment of Relapsed or Refractory Hodgkin Lymphoma

Blood and Lymphatic Cancer: Targets and Therapy
2012English

Brentuximab Vedotin in Patients With Relapsed HIV-Related Lymphoma

Journal of the National Comprehensive Cancer Network : JNCCN
MedicineOncology
2014English

High Response Rates and Safe Toxic Profile of Brentuximab Vedotin/Bendamustine Combination in Heavily Pretreated Patients With Relapsed/Refractory Hodgkin Lymphoma (HL)

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Nivolumab Combined With Brentuximab Vedotin for Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma: Efficacy and Safety From the Phase 2 Checkmate 436 Study

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy